Phase II Panitumumab-IRDye800 in Head & Neck Cancer

NCT04511078 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Panitumumab-IRDye800

Sponsor

University of Alabama at Birmingham